What is GentiBio?
Founded in 2020, GentiBio is a biotherapeutics company at the forefront of synthetic biology and immunology. The firm specializes in the development of engineered regulatory T cells (Tregs) designed to restore immune tolerance. By programming these cells to address the underlying causes of autoimmune, alloimmune, autoinflammatory, and allergic diseases, GentiBio aims to move beyond symptomatic management toward curative therapeutic interventions.
The company's market position is defined by its sophisticated platform technology, which allows for the precise engineering of Tregs to target specific disease pathways. This capability places GentiBio in a competitive tier of next-generation cell therapy developers, attracting significant interest from institutional investors focused on high-impact, evidence-based healthcare innovation.
How much funding has GentiBio raised?
GentiBio has raised a total of $157M across 1 funding round:
Series A
$157M
Series A (2021): $157M with participation from Matrix Capital Management, RA Capital Management, OrbiMed, Avidity Partners, and JDRF T1D Fund
Key Investors in GentiBio
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools.
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains, managing capital across biopharmaceuticals and medical devices.
JDRF T1D Fund
The T1D Fund is a scaled venture impact fund dedicated to accelerating treatments, prevention, and cures for the 9 million people living with Type 1 Diabetes through strategic investments in innovative therapies.
What's next for GentiBio?
With the successful closure of its Series A round, GentiBio is entering a high-growth phase characterized by intensive clinical development and operational scaling. The strategic roadmap involves advancing its lead candidates through preclinical validation and into human trials, a process that requires both rigorous scientific execution and robust capital management.
Looking ahead, the company will likely focus on expanding its internal research capabilities and strengthening its intellectual property portfolio. The involvement of specialized healthcare investors suggests a long-term commitment to navigating the complex regulatory and clinical hurdles inherent in cell therapy. As GentiBio continues to refine its Treg platform, the focus will remain on demonstrating safety and efficacy, which will be the primary drivers for future valuation milestones and potential strategic partnerships within the broader biopharmaceutical ecosystem.
